Abstracts tagged "prevention"

Abstract Number: 0616 • ACR Convergence 2023
Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study
Lea Meir¹, Tegveer Sandhu², Weiwei Chi² and Gabriela Santiago², ¹Icahn School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…
Abstract Number: 1895 • ACR Convergence 2023
Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies
Pritee Shrestha¹, Peter Larsen¹ and Pablo Weilg Espejo², ¹Mercy One North Iowa Medical Center, Mason City, IA, ²Boston Medical Center, Chelsea, MA
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of cardiovascular disease (CVD). Despite multiple CVD risk tools available, reliability to RA population is…
Abstract Number: 0742 • ACR Convergence 2023
Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes
Natalie McCormick¹, Chio Yokose², Na Lu³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Sharon Abada¹, Jing Li¹, Gary Tarasovsky², Cherish Wilson³, Jinoos Yazdany¹, Mary Whooley¹ and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²San Francisco VA, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…
Abstract Number: 2027 • ACR Convergence 2023
Developing and Implementing a Pilot Educational Intervention to Improve Readiness for Self-Management Among Patients with Rheumatic Diseases in Uganda
Trina Pal¹, Auther Jjunju², joshua bilsborrow³, Lillian Tugume⁴, Rachel Galvao³, Evelyn Hsieh⁵ and Mark Kaddumukasa⁴, ¹Section of Rheumatology, Yale School of Medicine, West Hartford, CT, ²The Arthritis Association of Uganda, Kampala, Uganda, ³Section of Rheumatology, Yale School of Medicine, New Haven, CT, ⁴Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda, ⁵Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health; Section of Rheumatology, VA Connecticut Healthcare System, Westport, CT
Background/Purpose: Self-management is an effective strategy for improving health outcomes among patients with chronic conditions such as rheumatic diseases. Patient education about self-management among patients…
Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Natalie McCormick¹, Chio Yokose², Jie Wei³, Na Lu⁴, Deborah Wexler¹, Mary De Vera⁵, J. Antonio Avina-Zubieta⁴, Yuqing Zhang⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Health Management Center, Xiangya Hospital Central South University, Changsha, China, ⁴Arthritis Research Canada, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁷Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…
Abstract Number: 2038 • ACR Convergence 2023
Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients
Minerva Nong¹, Medha Barbhaiya², Jonah Levine³, Vivian Bykerk⁴, Rachel Heise⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴Department of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Department of Population Health Sciences, Weill Cornell Medicine, New York, NY
Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…
Abstract Number: 0835 • ACR Convergence 2023
Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial
Andrew Cope¹, Marianna Jasenecova², Joana Vasconcelos³, Andrew Filer⁴, Karim Raza⁵, Sumera Qureshi², Maria Antonietta D'Agostino⁶, Iain McInnes⁷, John Isaacs⁸, Arthur Pratt⁹, Benjamin A Fisher⁴, Christopher Buckley¹⁰, Paul Emery¹¹, Pauline Ho¹², Maya Buch¹³, Coziana Ciurtin¹⁴, René Toes¹⁵, Thomas Huizinga¹⁵, Dirkjan van Schaardenburg¹⁶, Caroline Caroline¹⁷ and Toby Prevost³, ¹King's College London, London, United Kingdom, ²Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ³Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's College London, London, United Kingdom, ⁴University of Birmingham, Birmingham, United Kingdom, ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁶Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁹Translational & Clinical Research Institute, University of Newcastle, Newcastle, United Kingdom, ¹⁰University of Oxford, Oxford, United Kingdom, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ¹³University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ¹⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ¹⁵Leiden University Medical Center, Leiden, Netherlands, ¹⁶Reade, Amsterdam, Netherlands, ¹⁷King's Clinical Trials Unit, King's College London, London, United Kingdom
Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…
Abstract Number: 2055 • ACR Convergence 2023
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Racheal Githumbi¹, Susan Kuhn¹, Carla Osiowy², Jennifer DeBruyn¹, Marvin Fritzler¹, Nicole Johnson¹, Otto G Vanderkooi¹ and Heinrike Schmeling¹, ¹University of Calgary, Calgary, AB, Canada, ²National Microbiology Laboratory, Public Health Agency of Canada, Winnepig, MB, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…
Abstract Number: 0858 • ACR Convergence 2023
Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
Benjamin Terrier¹, Gregory Pugnet², Marie-Emmanuelle Sirieix³, Thomas Quemeneur⁴, Xavier Puéchal⁵, Francois Maurier⁶, Antoine Néel⁷, YGAL BENHAMOU⁸, Bernard Bonnotte⁹, Jean Schmidt¹⁰, Adrien Michon³, Antoine Baudet¹¹, Pierre Charles¹², Fleur Cohen¹³, Claire De Moreuil¹⁴, Emanuelle Dernis¹⁵, Pauline Belenotti¹⁶, Marc Ruivard¹⁷, Olivier Aumaitre¹⁸, Olivier Fain¹⁹, Raphaele Seror²⁰, Cécile-Audrey Durel²¹, Noémie Jourde-Chiche²², Estibaliz Lazaro²³, Gilles Chironi²⁴, Guillaume Armengol²⁵, Jeremy Bellien²⁵, Philippe Ravaud²⁶, Gabriel Baron²⁶ and Loic Guillevin²⁷, ¹Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France, ³HEGP, Paris, France, ⁴CH Valenciennes, Valenciennes, France, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, ⁶Hôpitaux privés de Metz, Vaux / Frankreich, France, ⁷CHU Nantes, Nantes, France, ⁸rouen university hospital, Rouen, France, ⁹Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ¹⁰CHU Amiens, Amiens, France, ¹¹CH Annecy, Annecy, France, ¹²Institut Mutualiste Montsouris, Service de Médecine Interne, Paris, France, ¹³Sorbonne Université, Paris, France, ¹⁴CHU de Brest, Brest, France, ¹⁵CH Le Mans, Le Mans, France, ¹⁶CHU Marseille, Marseille, France, ¹⁷CHU Clermont Ferrand, Clermont Ferrand, France, ¹⁸CHU Saint Antoine, Paris, France, ¹⁹Hopital SAINT ANTOINE APHP, Paris, France, ²⁰University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ²¹CHU Lyon, Lyon, France, ²²AP-HM, Marseille, France, ²³Bordeaux Hospital University, Pessac, France, ²⁴Monaco, Monaco, Monaco, ²⁵CHU Rouen, Rouen, France, ²⁶Paris Cité University, Paris, France, ²⁷University Paris Descartes, Paris, France
Background/Purpose: Despite more effective therapeutic strategies in ANCA-associated vasculitis (AAV), there is still a significant risk of morbidity and mortality, mainly due to infection, and…
Abstract Number: 2132 • ACR Convergence 2023
Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates
Claire Daien¹, Vera Georgescu², Guillaume Decarriere³, Gael Mouterde³, Cedric Lukas⁴, Gregoire Mercier² and JACQUES MOREL⁵, ¹University Hospital, Montpellier, France, ²Department of Medical Information, Montpellier, France, ³Rheumatology, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵Protocole thérapeutique immuno-rhumatologie, Montpellier, France
Background/Purpose: Systematic screening for multimorbidities has been carried out since 2014 at Montpellier University Hospital in patients with chronic inflammatory rheumatism (IRD). The aim of…
Abstract Number: 0938 • ACR Convergence 2023
Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum
Sunhwa Kim¹, Thierry Sornasse², Vishal Kakkar³, Rebecca Ross⁴, Yingtao Bi⁵, Hengcheng Hu², Lisa Hazelwood², Lauren Reinke-Breen⁶, jozsef karman⁷, Chris Butler², Jennifer Van Camp² and Francesco Del Galdo⁸, ¹AbbVie, Inc., South San Francisco, CA, ²AbbVie, Inc., North Chicago, IL, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵AbbVie, Inc., Worcester, MA, ⁶AbbVie, Inc., Vernon Hills, IL, ⁷AbbVie, Inc., San Francisco, CA, ⁸University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…
Abstract Number: 2283 • ACR Convergence 2023
Anti-SARS-CoV-2 Vaccination Among Patients Living with Systemic Lupus Erythematosus in Sweden: Coverage and Clinical Effectiveness
Arthur Mageau¹, Julia Simard², Elisabet Svenungsson³ and Elizabeth Arkema⁴, ¹Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden / Internal Medicine Unit, Hopital Bichat, Paris, France, ²Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ³Department of Medicine Solna, Unit of Rheumatology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine Solna, Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Real-world data assessing the effectiveness of the anti-SARS-CoV2 vaccination in patients living with systemic lupus erythematosus (SLE) are currently lacking. We aimed to describe…
Abstract Number: 1087 • ACR Convergence 2023
Characterizing Herpes Zoster Vaccination Patterns in Rheumatoid Arthritis Patients in a Tertiary Care Clinic: A Quality Improvement Approach
Sara Faghihi-Kashani, Arooj Babar and Janice Lin, Stanford University, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) face an increased risk of herpes zoster (HZ) infection, notably those on immunosuppressive therapy. Herpes zoster infection is associated…

« Previous Page
1
…
5
6
7
8
9
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].